Merck Suvorexant Scheduled, But DEA Delays Remain an Issue
This article was originally published in RPM Report
Executive Summary
DEA scheduled Merck’s Belsomra (suvorexant) August 28, only two weeks after its August 13 approval – much faster than the year-long wait for some drugs. But don’t take that to mean that the DEA process is moving faster for new drugs.